Your Health, We Care
POETYK PSO-3 is a phase III randomized controlled study conducted in an Asian population with the use of Deucravacitinib. After continuous treatment with Deucravacitinib, the response rates to PASI 75 and PASI 90 were 68.8% and 38.2%, respectively, which were significantly better than the control group.
The latest 4-year follow-up results of the global Phase III long-term expansion trial POETYK PSO-LTE show a stable and increasing trend in all key efficacy indicators of deuteroxenib.
